Free Trial

Douglas Tsao Analyst Performance

Senior Analyst at HC Wainwright

Douglas Tsao is a stock analyst at HC Wainwright in the medical sector, covering 43 publicly traded companies. Over the past year, Douglas Tsao has issued 70 stock ratings, including buy and hold recommendations. While full access to Douglas Tsao's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Douglas Tsao's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
202 Last 10 Years
Buy Recommendations
85.57% 172 Buy Ratings
Companies Covered
43 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy85.6%172 ratings
Hold12.9%26 ratings
Sell1.5%3 ratings

Out of 201 total stock ratings issued by Douglas Tsao at HC Wainwright, the majority (85.6%) have been Buy recommendations, followed by 12.9% Hold and 1.5% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
79.1% of companies on NASDAQ
34 companies
NYSE
18.6% of companies on NYSE
8 companies
NYSEAMERICAN
2.3% of companies on NYSEAMERICAN
1 company

Douglas Tsao, an analyst at HC Wainwright, currently covers 43 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
43 companies
100.0%

Douglas Tsao of HC Wainwright specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
20 companies
46.5%
PHARMACEUTICAL PREPARATIONS
10 companies
23.3%
MED - DRUGS
6 companies
14.0%
MED PRODUCTS
2 companies
4.7%
MED - GENERIC DRG
2 companies
4.7%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
2.3%
BIOTECHNOLOGY
1 company
2.3%
MED INSTRUMENTS
1 company
2.3%

About Douglas Tsao

Mr. Tsao is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on Biopharmaceuticals and Specialty Pharmaceuticals. Specific therapeutics areas include Endocrinology, Metabolic disease, Dermatology, and CNS in addition to other areas. Prior to joining H.C. Wainwright, Mr. Tsao was a senior equity research analyst at Barclays covering U.S. Specialty Pharmaceutical companies as well as small and midcap medical device companies. Mr. Tsao is recognized for his expertise in biosimilars and is a frequent speaker on this topic at industry conferences. Prior to Barclays Mr. Tsao worked at Lehman Brothers and his combined experience spans over ten years at these two firms. Mr. Tsao served as a Special Assistant to U.S. EPA Administrator Carol Browner from 1997-1999, received an MBA/MPH from U.C. Berkeley and graduated cum laude from Middlebury College with High Honors.
Follow on LinkedIn

Douglas Tsao's Ratings History at HC Wainwright

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
9/18/2025Boost Price Target$15.28$20.00Buy
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
9/17/2025Reiterated Rating$60.57$80.00Buy
Alkermes plc stock logo
ALKS
Alkermes
9/9/2025Reiterated Rating$28.45$46.00Neutral
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
9/8/2025Boost Price Target$14.36$34.00Buy
Immunovant, Inc. stock logo
IMVT
Immunovant
9/4/2025Reiterated Rating$16.70$35.00Buy
Rezolute, Inc. stock logo
RZLT
Rezolute
9/3/2025Reiterated Rating$7.17$14.00Buy
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
8/29/2025Reiterated Rating$1.09Neutral
Evotec AG stock logo
EVO
Evotec
8/14/2025Lower Price Target$3.81$7.00Buy
Biohaven Ltd. stock logo
BHVN
Biohaven
8/12/2025Reiterated Rating$13.42$30.00Buy
Evolus, Inc. stock logo
EOLS
Evolus
8/6/2025Lower Price Target$8.91$20.00Buy
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
8/6/2025Initiated Coverage$14.43$31.00Buy
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
8/5/2025Reiterated Rating$51.09$115.00Buy
argenex SE stock logo
ARGX
argenex
8/1/2025Boost Price Target$670.33$774.00Buy
Alkermes plc stock logo
ALKS
Alkermes
7/21/2025Reiterated Rating$26.37$46.00Neutral
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
7/18/2025Reiterated Rating$54.94$105.00Buy
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
7/3/2025Reiterated Rating$53.17$118.00Buy
argenex SE stock logo
ARGX
argenex
7/1/2025Reiterated Rating$551.22$720.00Buy
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
6/27/2025Reiterated Rating$29.99$81.00Buy
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
6/18/2025Reiterated Rating$11.11$18.00Buy
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
6/17/2025Reiterated Rating$52.02$118.00Buy
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
6/17/2025Reiterated Rating$9.07$12.00Neutral
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
6/11/2025Reiterated Rating$1.75$25.00Buy
argenex SE stock logo
ARGX
argenex
6/10/2025Reiterated Rating$583.62$720.00Buy
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
6/3/2025Reiterated Rating$50.15$80.00Buy
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
5/28/2025Reiterated Rating$10.76$18.00Buy
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
5/19/2025Reiterated Rating$44.49$80.00Buy
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
5/13/2025Reiterated Rating$35.85$53.00Buy
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
5/1/2025Reiterated Rating$37.64$105.00Buy
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
4/29/2025Reiterated Rating$1.03$7.00Buy
Rezolute, Inc. stock logo
RZLT
Rezolute
4/28/2025Reiterated Rating$3.68$14.00Buy
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
4/23/2025Reiterated Rating$13.76$34.00Buy
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
4/21/2025Reiterated Rating$10.22$18.00Buy
Evolus, Inc. stock logo
EOLS
Evolus
4/10/2025Reiterated Rating$10.37$27.00Buy
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
4/10/2025Reiterated Rating$40.42$80.00Buy
argenex SE stock logo
ARGX
argenex
4/8/2025Reiterated Rating$548.93$720.00Buy
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
4/1/2025Reiterated Rating$1.39$25.00Buy
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
4/1/2025Reiterated Rating$2.89$12.00Buy
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3/20/2025Reiterated Rating$3.04$18.00Buy
Immunovant, Inc. stock logo
IMVT
Immunovant
3/19/2025Reiterated Rating$18.71$51.00Buy
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
3/11/2025Reiterated Rating$1.04$7.00Buy
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3/10/2025Reiterated Rating$38.35$54.00Buy
Evolus, Inc. stock logo
EOLS
Evolus
3/5/2025Reiterated Rating$14.35$27.00Buy
Biohaven Ltd. stock logo
BHVN
Biohaven
3/4/2025Reiterated Rating$30.50$54.00Buy
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3/3/2025Reiterated Rating$3.28$18.00Buy
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
3/3/2025Lower Price Target$38.60$105.00Buy
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
3/3/2025Reiterated Rating$25.15$57.00Buy
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3/3/2025Reiterated Rating$39.03$54.00Buy
argenex SE stock logo
ARGX
argenex
2/28/2025Boost Price Target$624.70$720.00Buy
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
2/26/2025Reiterated Rating$1.79$5.00Neutral
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
2/25/2025Reiterated Rating$8.86$15.00Buy
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
2/24/2025Boost Price Target$38.75$54.00Buy
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2/18/2025Lower Price Target$1.87$3.00Buy
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
2/18/2025Reiterated Rating$2.34$25.00Buy
Evolus, Inc. stock logo
EOLS
Evolus
2/14/2025Reiterated Rating$15.04$27.00Buy
Rezolute, Inc. stock logo
RZLT
Rezolute
2/13/2025Reiterated Rating$4.79$14.00Buy
Alkermes plc stock logo
ALKS
Alkermes
2/13/2025Reiterated Rating$33.50$46.00Neutral
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2/13/2025Reiterated Rating$28.51$57.00Buy
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
2/12/2025Reiterated Rating$7.19$12.00Neutral
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2/11/2025Reiterated Rating$10.55$18.00Buy
Immunovant, Inc. stock logo
IMVT
Immunovant
2/7/2025Reiterated Rating$20.39$51.00Buy
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
2/7/2025Reiterated Rating$37.75$50.00Buy
Rezolute, Inc. stock logo
RZLT
Rezolute
2/5/2025Reiterated Rating$5.50$14.00Buy
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
1/23/2025Reiterated Rating$1.31$7.00Buy
Evolus, Inc. stock logo
EOLS
Evolus
1/22/2025Reiterated Rating$13.48$27.00Buy
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
1/21/2025Reiterated Rating$61.41$118.00Buy
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
1/17/2025Reiterated Rating$2.43$25.00Buy
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
1/17/2025Reiterated Rating$2.19$30.00Buy
argenex SE stock logo
ARGX
argenex
1/14/2025Reiterated Rating$671.62$717.00Buy
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
1/14/2025Reiterated Rating$28.59$57.00Buy
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
1/13/2025Reiterated Rating$40.59$81.00Buy